Prognostic value of baseline clinicopathological characteristics in first-line chemotherapy ± immunotherapy for extensive-stage small cell lung cancer: a retrospective cohort study.

ABSTRACT:

Background

The integration of chemotherapy and immunotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) has been adopted in clinical practice, yet the response to immune checkpoint inhibitors (ICIs) is variable, benefiting only a fraction of patients. The current absence of reliable biomarkers for predicting treatment response and prognosis represents a significant gap in knowledge, hindering the optimization of patient stratification and treatment planning. This retrospective cohort study aims to assess the potential predictive and prognostic significance of clinicopathological baseline features in ES-SCLC patients.

Methods

Our study retrospectively analyzed the data of consecutive patients with ES-SCLC treated with first-line etoposide p

SUBMITTER: Wu Y 

PROVIDER: S-EPMC11388222 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature